Urate Lowering and Cardiovascular Risk

So far, the main benefit of a treat-to-target (T2T) urate-lowering strategy has been the reduction and, ultimately, the disappearance of gout flares. Robust evidence from randomized trials has demonstrated that achieving and maintaining serum urate (SU) levels below 6 mg/dL (to convert to mmol/L, multiply by 0.0595) for several years markedly reduces the number of flares in patients with gout. So far, the main benefit of a treat-to-target (T2T) urate-lowering strategy has been the reduction and, ultimately, the disappearance of gout flares. Robust evidence from randomized trials has demonstrated that achieving and maintaining serum urate (SU) levels below 6 mg/dL (to convert to mmol/L, multiply by 0.0595) for several years markedly reduces the number of flares in patients with gout.